Registered	l number:	14070002
------------	-----------	----------

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 30 APRIL 2023

25 THE BISHOPS AVENUE LIMITED REGISTERED NUMBER: 14070002

BALANCE SHEET AS AT 30 APRIL 2023

	Note		2023 £
Fixed assets			
Investments	4		1
			1
Current assets			
Debtors: amounts falling due within one year	5	3,992,227	
	-	3,992,227	
Creditors: amounts falling due within one year	6	(267,892)	
Net current assets	-		3,724,335
Total assets less current liabilities			3,724,336
Creditors: amounts falling due after more than one year	7		(4,029,110)
Net (liabilities)/assets			(304,774)
Capital and reserves		•	
Called up share capital			1
Profit and loss account			(304,775)
			(304,774)

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

25 THE BISHOPS AVENUE LIMITED REGISTERED NUMBER: 14070002

BALANCE SHEET (CONTINUED) AS AT 30 APRIL 2023

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 20 February 2024.

G Dagan

Director

The notes on pages 4 to 7 form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 APRIL 2023

	share capital	Profit and loss account	Total equity
	£	£	£
Comprehensive income for the period			
Loss for the period		(304,775)	(304,775)
Other comprehensive income for the period			.
Total comprehensive income for the period	-	(304,775)	(304,775)
Contributions by and distributions to owners			
Shares issued during the period	1	-	1
Total transactions with owners	1	-	1
At 30 April 2023	1	(304,775)	(304,774)

The notes on pages 4 to 7 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 APRIL 2023

1. General information

25 The Bishops Avenue Limited is a private company limited by shares incorporated in the United Kingdom and registered in England & Wales. The address of its registered office is 14 Berkeley Street, Mayfair, London, W1J 8DX and its principal place of business is the same address.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

2.2 Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.3 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.4 Borrowing costs

All borrowing costs are recognised in profit or loss in the period in which they are incurred.

2.5 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

2.6 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.7 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 APRIL 2023

2. Accounting policies (continued)

2.8 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Investments in non-derivative instruments that are equity to the issuer are measured:

- at fair value with changes recognised in the statement of comprehensive income if the shares are publicly traded or their fair value can otherwise be measured reliably;
- at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or income as appropriate. The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 APRIL 2023

_		
3.	Employees	
	The average monthly number of employees, including the directors, during the period was as follows:	
		2023
		No.
		3
	Directors	
4.	Fixed asset investments	
••		
		Investments in
		subsidiary companies
		£
	Cost or valuation	
	Additions	1
	At 30 April 2023	1
5.	Debtors	
		2023
		£
	Amounts owed by subsidiary undertakings	3,992,226
	Other debtors	1
		3,992,227
6.	Creditors: Amounts falling due within one year	
		2023
		£
	Other creditors	262,892
	Accruals and deferred income	5,000
		267,892

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 APRIL 2023

7. Creditors: Amounts falling due after more than one year

2023

£

Other loans 4,029,110

4,029,110

8. Loans

Analysis of the maturity of loans is given below:

2023

£

Amounts falling due 1-2 years

Other loans 4,029,110

4,029,110

4,029,110

9. Related party transactions

The company has made a loan to its subsidiary company BMR Bishops Limited. At 30 April 2023 the loan balance was £3,992,226.

At 30 April 2023 the company owed £188,559 to the director B Margulies.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.